SCOUT MD™ for breast and axillary localisation: a narrative review toward a single radar-based platform Authors: Umar Wazir, Kefah Mokbel Published: 2026 ABSTRACT Background and ObjectiveWire-free localisation technologies have transformed the management of non-palpable breast lesions and pathological axillary lymph nodes. Radar-based localisation using the SAVI SCOUT® system is supported by extensive prospective clinical validation. SCOUT MD™ represents a next-generation radar platform incorporating miniaturised reflectors with unique signal identification designed to address recognised limitations of single-reflector systems. This narrative review aimed to examine the technical characteristics, regulatory status, clinical rationale and available evidence relating to SCOUT MD™, and to contextualise the platform within the broader landscape of wireless localisation technologies.MethodsA narrative review of literature published between January 2016 and January 2026 was undertaken using PubMed-indexed articles, regulatory documentation, manufacturer technical reports and reference lists from key studies of radar-based localisation systems.Key Content and FindingsSCOUT MD™ incorporates miniaturised 5-mm reflectors with up to four uniquely identifiable radar signatures enabling multi-target localisation. The reflectors can be discriminated individually by their unique signal signatures, without signal overlap. The system supports ultrasound, stereotactic mammography, magnetic resonance imaging (MRI) and computed tomography (CT)-guided deployment. Clinical evidence currently consists primarily of early technical reports and a single case report.ConclusionsSCOUT MD™ addresses recognised technical limitations of single-reflector radar localisation systems, particularly in multi-target localisation and tight bracketing scenarios. However, independent clinical evidence remains limited and prospective clinical studies are required to establish its comparative effectiveness. Introduction Wire-free localisation technologies have transformed the management of non-palpable breast lesions by improving patient comfort, scheduling flexibility, and operative workflow compared with traditional wire-guided localisation. Among these systems, radar‑based localisation using the SAVI SCOUT® platform has achieved widespread international adoption supported by prospective studies and pooled analyses demonstrating high localisation success rates and favourable oncological outcomes (1-3). Alternative wireless localisation technologies include magnetic seed localisation (Magseed®) (4), radiofrequency identification (RFID) systems (LOCalizer®) (5), and electromagnetic navigation systems such as EnVisio™. Each technology has distinct advantages and limitations relating to detection depth, imaging artefact and intra-operative workflow. SCOUT MD™ represents a miniaturised, multi-reflector evolution of this established radar-based technology, designed to address specific limitations of single-reflector systems rather than replace their validated core indications. Its development reflects the growing need for improved localisation in complex clinical scenarios, including tight bracketing, magnetic resonance imaging (MRI)-only lesions, and localisation of small pathological lymph nodes. The aim of this narrative review is to critically appraise the technical specifications, regulatory status, and potential clinical applications of SCOUT MD™ relative to the established SAVI SCOUT® platform. We present this article in accordance with the Narrative Review reporting checklist (available at https://gs.amegroups.com/article/view/10.21037/gs-2026-1-0031/rc). Methods This narrative review synthesised publicly available information on SCOUT MD™ published between January 2016 and January 2026. Sources included PubMed-indexed peer-reviewed publications, U.S. FDA regulatory documentation, manufacturer technical disclosures, and reference lists from key SAVI SCOUT® studies. Search terms included “SCOUT MD”, “SAVI SCOUT”, “radar localisation”, “breast localisation”, “axillary localisation”, “bracketing”, and “MRI artefact”. The search was performed by the senior author and cross-checked against reference lists of key publications. Evidence was categorised as: (I) independent peer-reviewed clinical evidence; (II) manufacturer technical documentation or regulatory submission data; and (III) early clinical reports. Where performance characteristics of SCOUT MD™ derive from manufacturer documentation or regulatory submissions, this is explicitly identified in the text, as such data are not subject to peer review and may not reflect independent real-world performance. Given the limited peer-reviewed SCOUT MD™ clinical evidence, a formal systematic review was not feasible. No new patient-level data were generated. The specifics of the methodology are summarised in Table 1. Table 1Search strategy summaryItemSpecificationDate of searchJanuary 12, 2026Databases and other sources searchedPubMed, US FDA documentation, manufacturer technical disclosures and reference lists from key SAVI SCOUT® studiesSearch terms used“SCOUT MD”, “SAVI SCOUT”, “radar localisation”, “breast localisation”, “axillary localisation”, “bracketing”, “MRI artefact”TimeframeJanuary 2016 to January 2026Inclusion and exclusion criteriaEnglish text availability. No specific exclusion criteriaSelection processSenior author (K.M.) conducted the search. Not enough material for a systematic reviewFDA, U.S. Food and Drug Administration; MRI, magnetic resonance imaging. Search strategy summary FDA, U.S. Food and Drug Administration; MRI, magnetic resonance imaging. The review was conducted in accordance with narrative review reporting standards, with explicit separation of technical, regulatory, and clinical evidence to minimise interpretive bias. Findings Limitations of the standard SAVI SCOUT® platform Despite extensive clinical validation, the standard SAVI SCOUT® platform has recognised limitations. Outside the United States, MRI-guided deployment for lesions visible only on MRI is not routinely feasible because MRI-compatible delivery instruments are not universally available. Although the SCOUT Bx™ Delivery System is MRI compatible in the USA, this limitation persists in many international settings, necessitating delayed localisation under mammographic or ultrasound guidance. Tight bracketing or localisation of multiple lesions in close proximity is also challenging because standard SAVI SCOUT® reflectors generate identical radar signals that cannot be distinguished intraoperatively, leading to signal overlap when reflectors are placed close together (1-3). In addition, the 12-mm reflector length, although advantageous for detectability, may be suboptimal for small axillary lymph nodes, particularly following neoadjuvant systemic therapy (NST), where nodes frequently measure less than 10 mm (6). Signal attenuation has been reported when reflectors are deployed within biopsy-related haematomas, although this can be mitigated with experience, strategic reflector placement, and incision planning (1-3). Reflector inactivation due to electrocautery or mechanical injury is uncommon and has been further reduced through design refinements incorporating additional capacitors (1-3). Technical and regulatory evolution from SAVI SCOUT® to SCOUT MD™ SCOUT MD™ represents a next-generation evolution of radar-based localisation technology. Its defining innovation is the ability to deploy up to four uniquely shaped reflectors, each generating a distinct radar signature that can be visually identified on mammography and audibly differentiated intraoperatively (Figures 1,2) (7). The reflectors can be discriminated individually by their unique signal signatures, with no minimum distance required to prevent signal overlap. Each reflector provides individualised depth and distance feedback, displayed in real time on a touchscreen console, allowing surgeons to toggle between or isolate specific signals intraoperatively (7-9). Four uniquely shaped SCOUT MD™ reflectors (J-shaped, L-shaped, double-J-shaped and J-L-shaped). Reflector length approximately 5 mm. Distinct radar signatures generated by each reflector, enabling reliable intraoperative differentiation by the operating surgeon. Images reproduced with permission from Merit Medical Systems. SCOUT MD™ dedicated multi-channel console. The SCOUT MD™ touchscreen console enables simultaneous real-time display and differentiation of up to four individually implanted reflectors, each identified by a unique colour-coded channel showing depth in millimetres. The console is not backward compatible with the standard SAVI SCOUT® console. The handheld intraoperative probe is shown connected to the console. Images reproduced with permission from Merit Medical Systems. SCOUT MD™ is compatible with ultrasound, stereotactic mammography, MRI, and CT-guided placement, enabling reflector deployment at the time of biopsy in the diagnostic pathway (7-9). Miniaturised reflectors of approximately 5 mm facilitate placement in anatomically constrained locations, including small breast lesions and pathological axillary lymph nodes compared with approximately 12 mm standard SAVI SCOUT® reflectors (7-9). MRI artefact associated with these reflectors has been reported to be consistently less than 2 mm, improving post-NST imaging interpretation (7-9). FDA regulatory status The U.S. FDA has granted SCOUT MD™ 510(k) clearance based on substantial equivalence to the SAVI SCOUT® system rather than on prospective comparative clinical outcomes (9). At the time of writing, CE marking in Europe remains under review. Table 2 summarises the comparative characteristics of the SAVI SCOUT® and SCOUT MD™ radar-based localisation systems. Table 2Comparative characteristics of SAVI SCOUT® and SCOUT MD™ radar-based localisation systemsFeatureSAVI SCOUT®SCOUT MD™Technology platformRadar-based wire-free localisationRadar-based wire-free localisation (next-generation)Reflector lengthApproximately 12 mmApproximately 5 mm (miniaturised)Number of distinguishable reflectorsSingle radar signatureUp to four uniquely shaped reflectors with distinct radar signaturesMulti-target localisationLimited; signal overlap when reflectors are closely spacedDesigned for reliable multi-target localisationTight bracketing capabilityPossible but limited by identical signalsOptimised for tight bracketing and circumferential localisationIntraoperative signal differentiationSingle audible/visual signalAudible and visual differentiation of individual reflectorsImaging guidance for deploymentUltrasound and stereotactic mammography; MRI-guided deployment limited outside the USAUltrasound, stereotactic mammography, MRI, and CT-guided deploymentMRI artefact sizeApproximately 4–5 mm (≈4.5 mm)Reported to be <2 mmSuitability for small axillary lymph nodesProven, but reflector size may limit placement in very small nodesImproved suitability due to smaller reflector sizeAxillary node localisationEffective even in nodes <10 mm with partial protrusionPossible advantage limited to anatomically constrained cases (e.g., proximity to major vessels)†Electrocautery resistanceImproved (additional capacitors in later iterations)Not independently assessed; updated components stated by manufacturer†Haematoma signal attenuationReported; mitigated by strategic placementNot yet evaluated; same mitigation strategies advised†Nickel/nitinol contentNitinol; nickel allergy contraindicationComposition not disclosed; verify with manufacturer†Console compatibilityDedicated SAVI SCOUT® consoleNew SCOUT MD™ multi-channel console required (not backward compatible)†Clinical evidence baseExtensive prospective studies, pooled analyses, and systematic reviewsSingle published clinical case report plus technical and regulatory dataRegulatory statusFDA cleared; CE markedFDA 510(k) cleared; CE marking pendingInter-reflector distance15–20 mm15–20 mm‡Workflow complexitySimple and well establishedIncreased complexity when multiple reflectors are deployedCost considerations~USD 400–600/reflector (published health-economic data)Commercial pricing not yet disclosed; additional console capital cost†Primary clinical roleStandard single-lesion breast and axillary localisationSelected cases requiring multi-target localisation, tight bracketing, MRI-only lesions, or small-node axillary localisation†, data from manufacturer technical documentation or FDA regulatory submission; not independently validated. ‡, SCOUT MD™ reflectors generate unique signatures designed to minimise overlap. A published case report (7) describes successful bracketing of a 40 mm lesion with inter-reflector spacing of approximately 15–20 mm, though no formal minimum spacing has been validated. CE, Conformité Européenne; CT, computed tomography; FDA, U.S. Food and Drug Administration; MRI, magnetic resonance imaging. Comparative characteristics of SAVI SCOUT® and SCOUT MD™ radar-based localisation systems †, data from manufacturer technical documentation or FDA regulatory submission; not independently validated. ‡, SCOUT MD™ reflectors generate unique signatures designed to minimise overlap. A published case report (7) describes successful bracketing of a 40 mm lesion with inter-reflector spacing of approximately 15–20 mm, though no formal minimum spacing has been validated. CE, Conformité Européenne; CT, computed tomography; FDA, U.S. Food and Drug Administration; MRI, magnetic resonance imaging. Console compatibility and capital cost The SCOUT MD™ multi-channel console (Figure 2) is not backward compatible with the standard SAVI SCOUT® console. Centres transitioning from SAVI SCOUT® will require new capital investment. Commercial pricing for SCOUT MD™ had not been disclosed by Merit Medical Systems at the time of writing; formal health-economic analysis will only be possible once pricing data are available. For context, published health-economic analyses have reported approximate per-procedure unit costs for SAVI SCOUT® reflectors in the range of USD 400–600 (1-3) (Table 3). Table 3Comparison of wireless breast localisation technologiesFeatureSAVI SCOUT®SCOUT MD™†Magseed®LOCalizer® (RFID)EnVisio™TechnologyRadar wire-freeRadar wire-free (next-gen)Magnetic seedRFID tagRadiofrequencyMarker size~12 mm~5 mm†~5 mm~8.5 mm~9 mmMulti-targetLimited (signal overlap)Up to 4 unique signatures†PossiblePossible (unique IDs)Single markerMRI guidanceLimited outside USAUS, stereo, MRI, CT†CompatibleCompatibleCompatibleMRI artefact~4–5 mm<2 mm†,‡~5 mm~5 mm~3 mmTissue depth>40 mm>40 mm†~30 mm~30 mm~30 mmClinical evidenceExtensiveSingle case report + mfr/reg dataExtensive (>1,500 cases)Single-centre studiesLimitedRegulatory statusFDA + CEFDA 510(k); CE pendingFDA + CEFDA + CEFDA clearedNickel/nitinolYes (nitinol)Not disclosed†NoNoNoConsole compatibilityDedicated SAVI consoleNew SCOUT MD console required†Handheld readerHandheld readerHandheld readerPublished unit cost~USD 400–600/reflectorNot yet disclosed~USD 400–500~USD 350–500Not published†, data for SCOUT MD™ derive from manufacturer technical documentation or FDA regulatory submissions and have not been independently validated in peer-reviewed clinical studies. ‡, MRI artefact <2 mm is manufacturer-reported. CE, Conformité Européenne; CT, computed tomography; FDA, U.S. Food and Drug Administration; mfr, manufacturer; MRI, magnetic resonance imaging; reg, regulatory; RFID, radiofrequency identification; stereo, stereotactic mammography; US, ultrasound. Comparison of wireless breast localisation technologies †, data for SCOUT MD™ derive from manufacturer technical documentation or FDA regulatory submissions and have not been independently validated in peer-reviewed clinical studies. ‡, MRI artefact <2 mm is manufacturer-reported. CE, Conformité Européenne; CT, computed tomography; FDA, U.S. Food and Drug Administration; mfr, manufacturer; MRI, magnetic resonance imaging; reg, regulatory; RFID, radiofrequency identification; stereo, stereotactic mammography; US, ultrasound. Learning curve Experience with first-generation SAVI SCOUT® demonstrates a short and predictable learning curve for radiologists and surgeons, with rapid attainment of technical proficiency and workflow integration (1-3). In centres already using SAVI SCOUT®, transition to SCOUT MD™ is expected to require minimal additional training because the core localisation principles, console interface, and intraoperative workflow are preserved (7-9). The incremental complexity of multi-reflector differentiation is intuitive and unlikely to represent a barrier to implementation. Pragmatic implementation through structured audit Given FDA clearance (9) and extensive experience with the first-generation SAVI SCOUT® system (1-3), a pragmatic implementation pathway may be considered. Early-adopting centres could introduce SCOUT MD™ within a prospective, registry-linked clinical audit framework. A sample size of approximately 70 consecutive cases may provide adequate power to detect clinically meaningful performance differences compared with the centre’s established localisation method. The audit should capture successful localisation rate (primary endpoint), operative time, margin positivity and re-excision rates, technical failures, and patient experience. If non-inferior performance is demonstrated, centres could consider broader routine use. Clinical rationale for multi-reflector localisation The principal rationale underpinning SCOUT MD™ is device miniaturisation combined with multi-target versatility, particularly in scenarios requiring tight bracketing or localisation of extensive disease exceeding 30 mm (Figure 3). Although approximately 10% of lesions currently undergo bracketing (10,11), this proportion is expected to rise. Increasing adoption of oncoplastic techniques (12), increasing utility of breast MRI together with a growing preference for breast-conserving surgery for larger and multifocal disease to avoid mastectomy, are supported by contemporary evidence demonstrating an overall survival advantage for breast-conserving surgery plus radiotherapy compared with mastectomy in appropriately selected patients (13). In parallel, wider availability of effective wire-free localisation platforms may reduce technical barriers to complex localisation. Mammographic confirmation of reflector placement bracketing a 40-mm region of ductal carcinoma in situ associated microcalcifications. Four unique SCOUT reflectors were each placed around the 4 cm area of calcifications. Specifically, a double L SCOUT was advanced into the proximal aspect of the group of calcifications. Similarly, two double J SCOUT reflectors were deployed in the lateral aspect and within the medial aspect of the calcifications. Reproduced from LaRussa et al., Frontiers in Surgery, 2025 (CC-BY 4.0) (7). In targeted axillary dissection, lymph nodes following NST are often small, fibrotic, or partially regressed, making secondary localisation challenging (6). Localisation of pathological lymph nodes at the time of diagnostic biopsy has been advocated to improve surgical accuracy (6,14). In this context, the smaller reflector size and distinct signal identity of SCOUT MD™ may offer advantages over standard single-reflector systems, pending prospective validation (7-9). Similarly, tight bracketing in patients with small breast volumes or multifocal disease may benefit from uniquely identifiable reflectors that minimise signal overlap, a recognised limitation when standard SAVI SCOUT® reflectors are placed in close proximity (1-3). MRI-only lesions represent another potential application; approximately 1.5% of breast cancers detected in supplemental screening are visible only on MRI (15), and SCOUT MD™ enables wire-free MRI-guided localisation of such lesions (7-9,15). Bracketing and multi-target surgery For most lesions measuring 30 mm or less, a single centrally placed standard SAVI SCOUT® reflector achieves excellent oncological outcomes, with reported re-excision rates below 5% (4). Routine bracketing in this group is therefore neither necessary nor cost-effective (4,10,11). In contrast, lesions exceeding 30 mm, multifocal disease, or cases in which cosmetic preservation is paramount may benefit from tighter circumferential bracketing enabled by SCOUT MD™ (Figure 3) (7,10-12). This approach may reduce unnecessary excision of normal tissue and improve aesthetic outcomes, although confirmation in prospective clinical studies is required. In extensive ductal carcinoma in situ (DCIS), disease extent often exceeds the distribution of mammographic microcalcifications, and non-mass MRI enhancement does not reliably predict the true extent of low-grade DCIS (15,16). In such settings, even advanced localisation technologies cannot fully compensate for biological and imaging limitations (15,16). Replacing the standard SAVI SCOUT® system with SCOUT MD™ for single-reflector localisation could permit platform consolidation, but this must be balanced against higher capital costs and the absence of comparative clinical outcome data. The clinical need for advanced radar-based localisation systems such as SCOUT MD™ is substantial and may expand. Bracketing is required in approximately 10% of localisation procedures (10,11). However, there are no standardised indications for bracketing of breast tumours, and practice varies considerably between centres, with a range of 15 to 95 mm (10). The average lesion size in published studies has demonstrated a considerable variation. Civil et al. reported an average tumour size of 24 mm, Liberman and colleagues reported an average size of 35 mm and Lyons et al. reported an average tumour size of 50 mm (10,11,17). Bracketed localisation has most commonly been used for tumours with a large disease span, multifocality, and those with a DCIS or invasive lobular carcinoma component. Although these features are typically associated with higher rates of positive margins, the reported rates of additional surgery following bracketed localisation are comparable to the national average for all breast-conserving surgery procedures. It should also be highlighted that the relative size of the breast is a significant contributing factor to the indication for bracketing. In patients with relatively small breasts, tight bracketing can be particularly beneficial for smaller disease footprints than 30 mm to ensure accurate excision of the disease with minimal removal of surrounding healthy breast tissue, thereby helping to maintain an optimal aesthetic outcome. Extrapolated nationally, assuming preoperative localisation is performed in approximately 30% of the 1 million breast biopsies undertaken annually in the United States, an estimated 30,000 women per year would require bracketing localisation (10,11). This highlights a clear unmet need for technologies capable of accurate multi-target localisation, for which SCOUT MD™ is specifically designed (7-9). Clinical scenarios and recommended approach Although SCOUT MD™ addresses technical limitations of single-reflector systems, its clinical role should be guided by evidence-based patient selection. Table 4 summarises recommended clinical scenarios based on current technical data and early clinical experience (7-9). Given the limited prospective comparative data, these recommendations are provisional. Table 4Provisional guidance framework for radar-based localisation: SAVI SCOUT® versus SCOUT MD™ (pending prospective validation)Clinical scenarioRecommended systemStrength of recommendation†RationaleSingle non-palpable lesion <30 mmSAVI SCOUT®StrongWell validated, cost-effective; re-excision rates <5%Multifocal disease or extensive DCIS >30 mm requiring bracketingSCOUT MD™ (provisional)WeakUniquely identifiable reflectors enable tight bracketing and may reduce excision volume; prospective validation requiredMRI-only lesionsSCOUT MD™ (provisional)Moderate (technical only)May enable wire-free MRI-guided localisation at diagnosis; not independently validatedTargeted axillary dissection post-NST with small (<10 mm) nodesSCOUT MD™ (provisional)Weak (theoretical advantage)Miniaturised reflector may improve placement in small, fibrotic, or regressed nodes; clinical validation pendingUnifocal localisation in resource-constrained settingsSAVI SCOUT®Strong (cost-effectiveness)Lower capital and consumable costs with proven clinical effectivenessMultiple synchronous lesions in different quadrants (≥2 cm apart)SAVI SCOUT®Moderate (established practice)Standard reflectors perform well when adequately spaced; signal overlap unlikelyMultiple closely spaced lesions in small breast volumeSCOUT MD™ (provisional)Weak (technical advantage)Distinct radar signatures minimize signal overlap; clinical benefit unprovenLocalisation at time of diagnostic biopsy (MRI, CT, or US-guided)SCOUT MD™ (provisional)Moderate (workflow advantage)Multimodality compatibility; cost and deployment ergonomics require prospective evaluation†, strength of recommendation based on quality and extent of supporting evidence: Strong: supported by multiple prospective studies, systematic reviews, or pooled analyses; Moderate: supported by technical data, regulatory documentation, and/or single-center prospective studies; Weak: based primarily on limited early clinical evidence, technical specifications, or extrapolation from related evidence; prospective validation required. CT, computed tomography; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging; NST, neoadjuvant systemic therapy; US, ultrasound. Provisional guidance framework for radar-based localisation: SAVI SCOUT® versus SCOUT MD™ (pending prospective validation) †, strength of recommendation based on quality and extent of supporting evidence: Strong: supported by multiple prospective studies, systematic reviews, or pooled analyses; Moderate: supported by technical data, regulatory documentation, and/or single-center prospective studies; Weak: based primarily on limited early clinical evidence, technical specifications, or extrapolation from related evidence; prospective validation required. CT, computed tomography; DCIS, ductal carcinoma in situ; MRI, magnetic resonance imaging; NST, neoadjuvant systemic therapy; US, ultrasound. For most patients requiring localisation of a single non-palpable lesion measuring less than 30 mm, the standard SAVI SCOUT® system remains highly effective, cost-efficient, and supported by extensive clinical validation (1-3). Routine adoption of SCOUT MD™ in this population would increase costs without demonstrable clinical benefit (10,11). SCOUT MD™ may offer advantages in selected scenarios, including multifocal disease or extensive in-situ carcinoma exceeding 30 mm requiring tight bracketing (7,10-12), MRI-only lesions (7-9,15), and targeted axillary dissection after NST where nodes are small or fibrotic (6-9). However, higher capital and consumable costs and increased workflow complexity necessitate careful patient selection and institutional cost-effectiveness analysis (7-9). In targeted axillary dissection (TAD), nodes following NST are often small, fibrotic or partially regressed, making localisation challenging (6). Localisation of pathological nodes at diagnostic biopsy has been advocated to improve surgical accuracy (14). In most cases, first-generation reflectors perform reliably; the potential advantage of SCOUT MD™ miniaturisation may be limited to nodes adjacent to major vascular structures (6). For MRI-only lesions (as discussed above), SCOUT MD™ may enable wire-free MRI-guided localisation at the time of diagnostic biopsy according to manufacturer documentation (7-9). Until prospective studies demonstrate reliable clinical performance, SCOUT MD™ should be considered complementary rather than a replacement technology (7-9). Assuming comparable clinical performance between the single SCOUT MD reflector and the first-generation SAVI SCOUT system, and a similar cost of consumables, it is plausible that breast centres currently using the SAVI SCOUT® platform may transition to SCOUT MD™ if comparable single-reflector performance and cost are confirmed. This would enhance clinical performance and expand capabilities in scenarios such as bracketing of extensive and multifocal disease, more precise localisation of pathological lymph nodes, and the selective use of multiple reflectors for bracketed localisation, as determined through multidisciplinary team discussion. Institutions adopting SCOUT MD™ should implement standardised selection criteria, prospectively monitor outcomes, and contribute to registry-based data collection. Radiologist’s perspective: deployment, ergonomics, and migration From a radiologist standpoint, wireless localisation systems differ in deployment ergonomics, imaging compatibility and workflow integration. Radar reflectors are generally straightforward to deploy and demonstrate minimal migration (1-3). Puente-Monserrat et al. report a 100% localisation success rate, a re-excision rate of 9.3%, and no device-related adverse events in the course of a prospective study of the use of radar-based localisation in 247 patients (18). Magnetic seed systems may interfere with surgical instruments (4), while RFID systems provide unique tag identification but may produce larger imaging artefacts (5). Electromagnetic navigation systems such as EnVisio™ enable realtime spatial navigation of surgical instruments relative to implanted markers (19). With regards to SAVI SCOUT® and SCOUT MD™, several practical considerations warrant attention. Miniaturisation from approximately 12 to 5 mm may reduce ultrasound visibility and the echogenic signature of the implanted reflector, potentially making post-deployment sonographic confirmation more challenging; no published data comparing ultrasound visibility between the two systems are currently available, and this represents a specific evidence gap for early adoption programmes. Lim et al. reported mechanical difficulty retracting the introducer deployment button with the first-generation SAVI SCOUT® system, which could affect deployment accuracy (20). Whether this has been redesigned in SCOUT MD™ is not stated in available manufacturer documentation; early-adopting centres should prospectively document deployment ergonomics. Migration rates for SAVI SCOUT® have been consistently low (≤1–2%) across prospective series (1-3); migration data for SCOUT MD™ are not yet available. The ability to deploy SCOUT MD™ reflectors at the time of diagnostic biopsy under MRI, computed tomography (CT) or ultrasound guidance (manufacturer data) offers a potential workflow advantage by eliminating a separate pre-operative localisation procedure, although the economic and logistical implications require prospective evaluation. Safety considerations Nickel allergy Standard SAVI SCOUT® reflectors contain nitinol (nickel-titanium alloy), and nickel hypersensitivity has been documented as a contraindication in prior publications (20-22). The alloy composition of SCOUT MD™ reflectors is not stated in available manufacturer documentation. Clinicians should verify material composition directly with the manufacturer before use in patients with known nickel allergy, and should not assume the contraindication profile is identical to SAVI SCOUT® until formally published. Electrocautery resistance Electrocautery-related inactivation was a recognised early limitation of SAVI SCOUT® that was substantially mitigated through incorporation of additional capacitors in later design iterations (1-3). Manufacturer documentation for SCOUT MD™ states that updated electronic components are incorporated; however, no independently published data directly comparing electrocautery resistance between SCOUT MD™ and SAVI SCOUT® are available. Prospective studies should document intraoperative inactivation events. Haematoma signal attenuation Signal attenuation due to post-biopsy haematoma has been described for SAVI SCOUT® (1-3). Whether SCOUT MD™ is more or less susceptible to this phenomenon is unknown. Clinicians should apply the same mitigation strategies established for SAVI SCOUT® (strategic placement, avoidance of direct haematoma implantation, incision planning) until comparative data are available. Evidence gaps and research priorities The following key clinical endpoints have not been reported for SCOUT MD™ in peer-reviewed literature and represent priorities for prospective evaluation: ❖ Deployment success rate under ultrasound, stereotactic, MRI, and CT guidance; ❖ Deployment success rate under ultrasound, stereotactic, MRI, and CT guidance; ❖ Reflector migration rate and positional stability; ❖ Reflector migration rate and positional stability; ❖ Complication rates (haematoma, infection, allergic reaction); ❖ Complication rates (haematoma, infection, allergic reaction); ❖ Surgical margin positivity and re-excision rates; ❖ Surgical margin positivity and re-excision rates; ❖ Reflector retrieval success rate; ❖ Reflector retrieval success rate; ❖ Intraoperative signal differentiation accuracy in vivo; ❖ Intraoperative signal differentiation accuracy in vivo; ❖ Ultrasound visibility of the miniaturised 5-mm reflector; ❖ Ultrasound visibility of the miniaturised 5-mm reflector; ❖ Electrocautery resistance compared with first-generation reflectors; ❖ Electrocautery resistance compared with first-generation reflectors; ❖ MRI artefact independently validated; ❖ MRI artefact independently validated; ❖ Deployment ergonomics and introducer button mechanics; ❖ Deployment ergonomics and introducer button mechanics; ❖ Cost-effectiveness relative to SAVI SCOUT® for single and multi-reflector use. ❖ Cost-effectiveness relative to SAVI SCOUT® for single and multi-reflector use. Future prospective studies should adopt the reporting standards established in the SAVI SCOUT® literature (1-3,6,18) and be conducted within structured audit frameworks with registry linkage. Conclusions SCOUT MD™ serves as both a complementary technology for complex scenarios and a replacement platform enabling consolidation for centres currently using SAVI SCOUT®. Assuming comparable single-reflector performance and consumable cost, SCOUT MD™ offers clear technical advantages for selected indications—particularly tight bracketing, MRI-only lesions, and small-node axillary localisation—while preserving overall cost-effectiveness through judicious, MDT-led deployment of multiple reflectors. Until prospective comparative data are available, adoption within structured audit and registry-based evaluation is appropriate to define its true clinical value and optimal patient selection criteria. The economic impact of SCOUT MD™ is therefore largely dependent on selective multi-reflector use for tight bracketing. When deployed as a single-reflector platform, SCOUT MD™ is expected to demonstrate equivalent performance and comparable consumable costs to SAVI SCOUT®, enabling platform consolidation without financial penalty. Formal health-economic modelling is now required to define the cost-utility threshold at which multi-reflector deployment becomes clinically and financially justified. Supplementary The article’s supplementary files as Available at https://gs.amegroups.com/article/view/10.21037/gs-2026-1-0031/prf